Stock listing
TWSE:1783 Maxigen Biotech Inc. (和康生) 股價
Follow Maxigen Biotech Inc. into a list and get an email when it puts out news.
Share price · TWSE:1783
$31.80 TWD -3.50 (-9.9%)
Close on Nov 20, 2026
- Day range
- $31.60 – $34.10 TWDNov 20, 2026
- Volume
- 172,217 sharesNov 20, 2026
- Market cap
- $2.85B TWDAt the close on Nov 20, 2026 · price × 89.70M shares outstanding
- 52-week range
- $31.60 – $48.30 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.53M TWDMedian day 58,553 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TWSE:1783 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $31.80 | -3.50 | -9.9% | $33.80 | $34.10 | $31.60 | 172,217 | |
| $35.30 | +0.05 | +0.1% | $35.55 | $35.55 | $34.50 | 46,082 | |
| $35.25 | +0.25 | +0.7% | $34.95 | $35.50 | $34.60 | 55,900 | |
| $35.00 | -1.00 | -2.8% | $35.65 | $35.65 | $34.90 | 42,115 | |
| $36.00 | +0.20 | +0.6% | $36.10 | $36.40 | $35.45 | 60,218 | |
| $35.80 | -0.20 | -0.6% | $37.00 | $37.00 | $35.80 | 78,516 | |
| $36.00 | +0.75 | +2.1% | $35.80 | $36.15 | $35.55 | 99,240 | |
| $35.25 | 0.00 | 0.0% | $35.45 | $35.45 | $34.80 | 69,256 | |
| $35.25 | +0.55 | +1.6% | $34.70 | $35.35 | $34.70 | 94,360 | |
| $34.70 | -0.50 | -1.4% | $34.30 | $35.40 | $33.50 | 121,262 | |
| $35.20 | -0.15 | -0.4% | $35.70 | $35.70 | $34.90 | 33,140 | |
| $35.35 | +0.40 | +1.1% | $35.30 | $35.40 | $34.80 | 62,300 | |
| $34.95 | -0.05 | -0.1% | $35.00 | $35.15 | $34.60 | 44,652 | |
| $35.00 | -0.10 | -0.3% | $35.60 | $35.70 | $34.90 | 109,147 | |
| $35.10 | -1.00 | -2.8% | $36.05 | $36.05 | $35.10 | 115,121 | |
| $36.10 | -0.50 | -1.4% | $36.55 | $36.55 | $35.70 | 241,272 | |
| $36.60 | +0.30 | +0.8% | $36.25 | $36.60 | $36.25 | 35,333 | |
| $36.30 | -0.10 | -0.3% | $36.30 | $36.40 | $36.20 | 36,551 | |
| $36.40 | 0.00 | 0.0% | $36.40 | $36.40 | $36.40 | 0 | |
| $36.40 | +0.10 | +0.3% | $36.40 | $36.50 | $36.10 | 75,400 | |
| $36.30 | -0.10 | -0.3% | $36.50 | $37.20 | $36.25 | 68,221 | |
| $36.40 | -0.60 | -1.6% | $36.80 | $36.80 | $35.85 | 122,353 | |
| $37.00 | -0.50 | -1.3% | $37.50 | $37.50 | $37.00 | 44,916 | |
| $37.50 | +0.10 | +0.3% | $37.50 | $38.50 | $37.50 | 108,691 | |
| $37.40 | -0.30 | -0.8% | $37.60 | $37.75 | $37.35 | 46,000 | |
| $37.70 | -0.10 | -0.3% | $38.00 | $38.00 | $37.45 | 63,056 | |
| $37.80 | -0.35 | -0.9% | $38.05 | $38.10 | $37.20 | 52,227 | |
| $38.15 | +0.05 | +0.1% | $38.10 | $38.25 | $38.00 | 29,000 | |
| $38.10 | -0.45 | -1.2% | $38.55 | $38.70 | $38.05 | 108,053 | |
| $38.55 | -0.05 | -0.1% | $38.55 | $38.60 | $38.25 | 100,105 | |
| $38.60 | +1.70 | +4.6% | $37.90 | $38.75 | $37.50 | 92,051 | |
| $36.90 | -0.15 | -0.4% | $37.05 | $37.15 | $36.70 | 32,381 | |
| $37.05 | -0.30 | -0.8% | $36.80 | $37.25 | $36.80 | 20,069 | |
| $37.35 | +0.10 | +0.3% | $36.90 | $37.35 | $36.90 | 43,000 | |
| $37.25 | +0.60 | +1.6% | $37.05 | $37.25 | $36.80 | 71,554 | |
| $36.65 | -0.05 | -0.1% | $36.45 | $37.00 | $36.45 | 25,010 | |
| $36.70 | +0.10 | +0.3% | $36.60 | $36.75 | $36.45 | 19,001 | |
| $36.60 | +0.20 | +0.5% | $36.40 | $36.75 | $36.30 | 54,831 | |
| $36.40 | -0.10 | -0.3% | $36.55 | $36.55 | $36.10 | 54,315 | |
| $36.50 | -0.20 | -0.5% | $36.75 | $36.75 | $36.40 | 63,014 | |
| $36.70 | +0.40 | +1.1% | $36.40 | $36.70 | $36.30 | 100,001 | |
| $36.30 | +0.05 | +0.1% | $36.30 | $36.40 | $36.20 | 35,100 | |
| $36.25 | +0.05 | +0.1% | $36.25 | $36.30 | $36.15 | 34,351 | |
| $36.20 | -0.20 | -0.5% | $36.50 | $36.50 | $36.20 | 56,050 | |
| $36.40 | 0.00 | 0.0% | $36.45 | $36.55 | $36.30 | 99,000 | |
| $36.40 | -0.65 | -1.8% | $36.40 | $36.65 | $36.35 | 59,107 | |
| $37.05 | -0.55 | -1.5% | $37.55 | $37.60 | $37.00 | 117,079 | |
| $37.60 | -0.20 | -0.5% | $37.80 | $37.85 | $37.55 | 59,105 | |
| $37.80 | -0.25 | -0.7% | $38.00 | $38.00 | $37.80 | 32,278 | |
| $38.05 | -0.25 | -0.7% | $39.00 | $39.00 | $38.00 | 79,107 | |
| $38.30 | -0.50 | -1.3% | $38.65 | $38.95 | $38.30 | 71,119 | |
| $38.80 | -0.30 | -0.8% | $39.05 | $39.45 | $38.80 | 32,148 | |
| $39.10 | -0.60 | -1.5% | $39.70 | $39.70 | $39.00 | 90,001 | |
| $39.70 | -1.65 | -4.0% | $39.35 | $39.95 | $39.35 | 98,000 | |
| $41.35 | +0.65 | +1.6% | $41.50 | $41.50 | $40.60 | 151,560 | |
| $40.70 | 0.00 | 0.0% | $40.90 | $40.90 | $40.40 | 56,256 | |
| $40.70 | +0.15 | +0.4% | $40.90 | $40.90 | $40.40 | 54,250 | |
| $40.55 | +0.15 | +0.4% | $40.30 | $40.70 | $40.10 | 53,000 | |
| $40.40 | +0.05 | +0.1% | $40.35 | $40.40 | $40.10 | 26,160 | |
| $40.35 | -0.05 | -0.1% | $40.45 | $40.45 | $40.05 | 58,000 | |
| $40.40 | -0.10 | -0.2% | $40.30 | $40.40 | $40.15 | 28,000 | |
| $40.50 | -0.40 | -1.0% | $41.05 | $41.05 | $40.50 | 52,000 |
Splits
1 split · TWSE:1783 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 11-for-10 | Split |
- Ticker
- TWSE:1783
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- TWSE
- Currency
- TWD
Latest news
Maxigen Biotech Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 12 in all · newest Aug 9, 2022 · oldest 2022
Valuation
P/E 9.8× against a median of 23.0×: 2nd lowest of 5 Medical devices & supplies companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.96B TWD
- P/E
- 9.8×
- EV/sales
- 2.3×
- EV/EBITDA
- 6.7×
- Price/book
- 1.9×
- Gross margin
- 69.9%
- Operating margin
- 30.4%
- Net margin
- 34.8%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Maxigen Biotech Inc. · TWSE:1783 | US$86.53M | US$59.38M | 9.8× | 2.3× | 6.7× | 1.9× | 34.8% | 0.1× | n/a |
| Stereotaxis, Inc. · AMEX:STXS | US$94.41M | US$92.90M | n/a | 3.0× | n/a | 4.4× | −70.9% | 0.1× | 1.03 |
| Gaush Meditech Ltd. · HKEX:2407 | US$94.33M | US$101.0M | 6.5× | 0.5× | 3.2× | 0.4× | 7.0% | 0.2× | n/a |
| SciVision Biotech Inc. · TWSE:1786 | US$88.98M | US$76.24M | 16.5× | 2.8× | 10.7× | 1.6× | 20.0% | 0.3× | n/a |
| Owlet, Inc. · NYSE:OWLT | US$87.58M | US$66.96M | n/a | 0.6× | n/a | 3.3× | −10.2% | 0.4× | 2.11 |
| EMvision Medical Devices Ltd. · ASX:EMV | US$87.37M | US$78.30M | n/a | n/a | n/a | 8.4× | n/a | 0.2× | n/a |
| Viromed Medical AG · XETR:VME | US$83.96M | US$83.66M | 127× | 15.0× | n/a | 8.1× | 11.9% | 0.0× | n/a |
| ICARES Medicus Inc · TPEX:6612 | US$83.86M | US$61.27M | 29.6× | 1.7× | 7.3× | 1.5× | 7.7% | 0.0× | n/a |
| Nyxoah SA · EURONEXT:NYXH | US$83.60M | US$6.53M | n/a | 0.3× | n/a | 0.9× | −443.2% | 0.3× | n/a |
| Optiscan Imaging Limited · ASX:OIL | US$83.05M | US$74.44M | n/a | 251× | n/a | 6.6× | n/a | 0.1× | n/a |
| EBR Systems, Inc. · ASX:EBR | US$79.78M | US$36.17M | n/a | n/a | n/a | 1.0× | n/a | 0.5× | n/a |
| Median of the others | US$85.66M | US$75.34M | 23.0× | 2.3× | 7.3× | 2.5× | 7.0% | 0.2× | 1.57 |
Team and board
| Director | Role |
|---|---|
| Vincent Lin | Chairman of the Board |
| Yung-Hsiang Lin | Chairman |
| Chen-Chen Fu | Director |
| Ching-Ting Chen | Director |
| Cong-Jie Qiu | Director |
| Shih-Ming Lai | Director |
| Shih-Ming Li | Independent Director |
| Sung-Yuan Liao | Independent Director |
| Tsiu-Yuan Li | Director |
| Zhong-Ming Zeng | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 3, 2023 · Before open | −2.3% |
| Q4 2022 | Mar 23, 2023 · Before open | +2.2% |
| Q3 2022 | Oct 25, 2022 · Before open | −0.9% |
| Q2 2022 | Aug 3, 2022 · After close | +0.1% |
| Q1 2022 | May 3, 2022 · After close | −2.1% |
| Q4 2021 | Mar 21, 2022 · Before open | +3.3% |
| Q3 2021 | Nov 3, 2021 · Before open | 0.0% |
| Quarter to Jun 30, 2021 | Jul 27, 2021 · Before open | +4.8% |
| Quarter to Mar 31, 2021 | May 14, 2021 · Before open | −5.7% |
| Quarter to Dec 31, 2020 | Mar 22, 2021 · After close | +9.9% |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 811.6M | 680.7M | 622.1M | 604.4M | 512.0M | 457.7M | 452.2M | 427.7M | 427.6M | 336.4M |
| Cost of revenue | 247.8M | 197.3M | 198.0M | 230.4M | 250.9M | 243.2M | 234.9M | 245.1M | 267.3M | 201.5M |
| Gross profit | 563.7M | 483.3M | 424.1M | 374.0M | 261.0M | 214.5M | 217.3M | 182.6M | 160.3M | 134.9M |
| Research and development | 126.1M | 111.8M | 68.6M | 99.6M | 75.7M | 69.2M | 66.9M | 50.7M | 43.3M | 36.3M |
| Selling, general and administrative | 183.9M | 82.2M | 72.6M | 63.0M | 52.8M | 50.2M | 44.6M | 44.9M | 46.9M | 60.4M |
| Operating income | 261.0M | 194.4M | 149.8M | 170.6M | 100.7M | 76.9M | 76.1M | 46.1M | 21.0M | -11.3M |
| Depreciation and amortization | 32.1M | 27.0M | 27.6M | 29.6M | 32.9M | 33.2M | 32.5M | 26.2M | 25.8M | 18.1M |
| EBITDA | 293.2M | 221.4M | 177.5M | 200.1M | 133.6M | 110.1M | 108.6M | 72.4M | 46.8M | 6.80M |
| Interest expense | 43.0K | 0 | 0 | 68.0K | 196.0K | 250.0K | 3.43M | 4.02M | 4.12M | 4.81M |
| Income before tax | 304.9M | 225.5M | 193.1M | 165.8M | 97.5M | 76.7M | 72.8M | 57.3M | 16.7M | -12.0M |
| Income tax | 39.6M | 35.4M | 27.3M | 26.4M | 9.80M | 13.4M | 12.7M | 253.0K | 908.0K | 288.0K |
| Net income | 265.3M | 190.2M | 165.8M | 139.4M | 87.7M | 63.3M | 60.1M | 57.1M | 15.8M | -12.2M |
| Earnings per share, basic | 2.96 | 2.12 | 1.85 | 1.56 | 1.04 | 0.79 | 0.68 | 0.67 | 0.21 | -0.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 576.2M | 639.1M | 431.1M | 790.9M | 513.3M | 209.8M | 267.6M | 184.8M | 182.2M | 96.6M |
| Short-term investments | 301.5M | 1.50M | 1.50M | 10.3M | 26.9M | 13.1M | 165.0M | 232.3M | 123.0M | 258.1M |
| Receivables | 132.2M | 103.9M | 97.1M | 100.1M | 114.4M | 100.3M | 97.8M | 86.5M | 126.1M | 110.3M |
| Inventory | 99.2M | 75.7M | 85.2M | 75.3M | 79.0M | 87.0M | 88.1M | 82.6M | 94.0M | 91.0M |
| Current assets | 1.12B | 830.3M | 619.6M | 993.2M | 783.6M | 432.1M | 640.2M | 599.5M | 585.1M | 574.0M |
| Property, plant and equipment | 434.6M | 465.5M | 481.5M | 502.1M | 494.0M | 502.0M | 503.2M | |||
| Goodwill | 1 | |||||||||
| Total assets | 1.89B | 1.58B | 1.49B | 1.45B | 1.27B | 956.5M | 1.19B | 1.14B | 1.10B | 1.10B |
| Accounts payable | 86.8M | 50.0M | 17.1M | 35.9M | 40.1M | 33.0M | 34.0M | 31.0M | 40.5M | 33.8M |
| Current liabilities | 349.1M | 205.9M | 131.4M | 151.5M | 116.1M | 86.6M | 321.9M | 292.4M | 83.0M | 87.7M |
| Long-term debt | 0 | 13.2M | 14.9M | |||||||
| Total debt | 101.4M | 50.0K | 9.74M | 12.1M | 14.7M | 213.2M | 14.9M | 16.5M | ||
| Total liabilities | 355.5M | 207.4M | 131.9M | 152.1M | 123.5M | 96.2M | 334.2M | 292.5M | 307.7M | 316.0M |
| Shareholders' equity | 1.54B | 1.38B | 1.36B | 1.30B | 1.14B | 860.2M | 851.3M | 843.0M | 796.3M | 781.4M |
| Shares outstanding | 89.6M | 89.7M | 89.5M | 89.4M | 84.1M | 80.6M | 87.8M | 85.3M | 76.5M | 76.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 290.2M | 298.2M | 171.2M | 268.3M | 117.6M | 74.4M | 94.4M | 170.6M | 41.2M | 34.7M |
| Capital spending | -82.6M | -31.8M | -22.4M | -14.4M | -15.4M | -11.3M | -23.7M | -20.2M | -29.0M | -72.7M |
| Free cash flow | 207.6M | 266.5M | 148.8M | 253.9M | 102.1M | 63.1M | 70.7M | 150.4M | 12.2M | -38.0M |
| Cash from investing | -383.0M | -29.1M | -490.2M | 10.4M | -2.77M | 139.1M | 42.6M | -142.3M | 50.3M | -141.8M |
| Cash from financing | 30.7M | -59.7M | -41.4M | -1.05M | 188.7M | -271.4M | -54.4M | -25.7M | -5.28M | -86.0M |
| Dividends paid | -74.4M | -89.0M | -42.4M | -56.3M | -54.2M | -51.9M | -10.8M | -10.8M | -10.8M | |
| Share buybacks | -100.0K | 0 | -33.1M | |||||||
| Change in cash | -62.9M | 208.0M | -359.9M | 277.6M | 303.5M | -57.9M | 82.8M | 2.63M | 85.6M | -196.0M |
Cap table
Built by 6ix from Maxigen Biotech Inc.’s releases
- Common shares
- 89,698,000
- Fully diluted
- 89,698,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 89,698,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 89,698,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chen-Chen Fu | Director · Since at least Nov 5, 2026 |
| Ching-Ting Chen | Director · Since at least Nov 5, 2026 |
| Cong-Jie Qiu | Director · Since at least Nov 5, 2026 |
| Shih-Ming Lai | Director · Since at least Nov 5, 2026 |
| Shih-Ming Li | Independent Director · Since at least Nov 5, 2026 |
| Sung-Yuan Liao | Independent Director · Since at least Nov 5, 2026 |
| Tsiu-Yuan Li | Director · Since at least Nov 5, 2026 |
| Vincent Lin | Chairman of the Board · Since at least Nov 5, 2026 |
| Yung-Hsiang Lin | Chairman · Since at least Nov 5, 2026 |
| Zhong-Ming Zeng | Independent Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Maxigen Biotech Inc.